Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
19 drugs in development
By Therapeutic Area
top 6
R&D Momentum
82/100
Pipeline Velocity
53/100
Trial Completion Rate
86/100
Pipeline Concentration
13/100
Pipeline Freshness
38/100
Strategic Signals
Activity
Last 14 days
Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration
Health Economic Impact of Robot-assisted Bariatric Surgery vs Conventional Laparoscopy: Prospective Multicenter Randomized Controlled Trial
Diving Into the in Vivo Noradrenergic System : Role of the alpha2C-adrenergic Receptors
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
Validation of the French Version of the OSA-18 Questionnaire
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)